Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2017

Open Access 01-12-2017 | Research article

The economic burden of adult asthma in Cyprus; a prevalence-based cost of illness study

Authors: Savvas Zannetos, Theodora Zachariadou, Andreas Zachariades, Andreas Georgiou, Michael A. Talias

Published in: BMC Public Health | Issue 1/2017

Login to get access

Abstract

Background

Asthma is one of the main non-infectious diseases of the respiratory system with substantial economic burden worldwide. The objective of this study was to estimate the economic burden of adult asthma in Cyprus during 2015.

Methods

A retrospective probabilistic prevalence-based cost of illness model was developed to calculate the economic burden of asthma including direct and indirect costs. The bottom-up approach (person-based data) was used for the calculation of direct costs while for the calculation of indirect costs the approach of human capital was employed. In addition, bootstrapped sensitivity analysis with 1000 bootstrap simulations was performed in order to calculate a 95% Confidence Interval (CI).

Results

Mean patient cost of asthma in Cyprus in 2015 was estimated at €579.64 (95% CI: €376.90–€813.68). Direct costs accounted for 82.08% of the overall expenses, €475.75 per patient (95% CI: €296.94–€697.69). Indirect costs of €103.89 (95% CI: €49.59–€181.46) accounted for 17.92% of the overall expenses.

Conclusion

This was the first study in Cyprus, which used bootstrapped prevalence-based cost of illness model to estimate the cost of asthma. This study confirms that asthma is an expensive disease for the society. In addition, it provides important information and analysis of the economic consequences of asthma to policy makers in order to strengthen surveillance of the disease as well as draft the national health policy accordingly.
Appendix
Available only for authorised users
Literature
1.
Health NIo, National Heart L, Institute B. Global initiative for asthma. Global strategy for asthma management and prevention. Revised. 2002.
2.
3.
Cruz AA, Bousquet J, Khaltaev N. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. Switzerland: World Health Organization; 2007.
4.
Harver HKA, Kotses H. Asthma, Health and Society. New York: Springer; 2010.
5.
Global Asthma Network. The Global Asthma Report 2014. Auckland, New Zealand; 2014.
6.
7.
Cyprus Government. European Health Survey. In. Cyprus Statistical Service, editor. Nicosia; 2010.
8.
9.
Åberg N. Asthma and allergic rhinitis in Swedish conscripts. Clin Exp Allergy. 1989;19(1):59–63.CrossRefPubMed
10.
Ciprandi G, Vizzaccaro A, Cirillo I, Crimi P, Canonica G. Increase of asthma and allergic rhinitis prevalence in young Italian men. Int Arch Allergy Immunol. 1996;111(3):279–83.CrossRef
11.
Jefferson T, Demicheli V, Mugford M. Elementary economic evaluation in health care. London: BMJ Publishing Group; 1996.
12.
Clabaugh G, Ward MM. Cost‐of‐Illness Studies in the United States: A Systematic Review of Methodologies Used for Direct Cost. Value Health. 2008;11(1):13–21.CrossRefPubMed
13.
Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy. 2006;77(1):51–63.CrossRefPubMed
14.
15.
Central Bank of Cyprus. Annual Economic Indicators. 2016. p. 1.
16.
Burney P, Luczynska C, Chinn S, Jarvis D. The European community respiratory health survey. Eur Respir J. 1994;7(5):954–60.CrossRefPubMed
17.
Gandek B, Ware JE. Methods for validating and norming translations of health status questionnaires: the IQOLA project approach. J Clin Epidemiol. 1998;51(11):953–9.CrossRefPubMed
18.
Beaton D, Bombardier C, Guillemin F, Ferraz MB. Recommendations for the cross-cultural adaptation of health status measures. New York: American Academy of Orthopaedic Surgeons; 2002. p. 1–9.
19.
Akinbami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert TV, Lee TA, et al. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol. 2012;129(3):S49–64.CrossRefPubMedPubMedCentral
20.
National Heart Lung Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma: full report. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; Maryland: 2007.
21.
22.
Collins D, Lapsley H. The Social Costs of Drug Abuse in Australia in 1988 and 1992: Monograph no. 30. 2004.
23.
24.
Graf von der Schulenburg J, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, et al. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health. 2008;11(4):539–44.CrossRefPubMed
25.
Government of Cyprus. Main Economic Indicators. Nicosia: Ministry of Finance; 2013. p. 1.
26.
27.
Ament A, Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy. 1993;26(1):29–42.CrossRefPubMed
28.
Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Economic evaluation in health care: merging theory with practice. 2001. p. 172–214.
29.
Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine: report of the panel on cost-effectiveness in health and medicine. New York: Oxford Univ Pr; 1996.
30.
Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. In: The Milbank Memorial Fund Quarterly Health and Society. 1982. p. 429–62.
31.
Hodgson TA. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res. 1982;4:129–64.
32.
Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 1979;7:1–26. View Article PubMed/NCBI Google Scholar.CrossRef
33.
Efron B. Better bootstrap confidence intervals. J Am Stat Assoc. 1987;82(397):171–85.CrossRef
34.
Microsoft Cooperation. Micorosoft Excel 2007. Redmond: Microsoft Cooperation; 2007.
35.
R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2015.
36.
37.
Dinmezel S, Ogus C, Erengin H, Cilli A, Ozbudak O, Ozdemir T, editors. The prevalence of asthma, allergic rhinitis, and atopy in Antalya, Turkey. Allergy and asthma proceedings; Rhode Island: OceanSide Publications, Inc.; 2005.
38.
Druss BG, Marcus SC, Olfson M, Pincus HA. The most expensive medical conditions in America. Health Aff. 2002;21(4):105–11.CrossRef
39.
40.
Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, et al. Direct and indirect costs of asthma to an employer. J Allergy Clin Immunol. 2002;109(2):264–70.CrossRefPubMed
41.
Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol. 2003;111(6):1212–8.CrossRefPubMed
42.
Szucs TD, Anderhub H, Rutishauser M. The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J. 1999;13(2):281–6.CrossRefPubMed
43.
Accordini S, Bugiani M, Arossa W, Gerzeli S, Marinoni A, Olivieri M, et al. Poor control increases the economic cost of asthma. Int Arch Allergy Immunol. 2006;141(2):189–98.CrossRefPubMed
44.
Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F, et al. Asthma severity and medical resource utilisation. Eur Respir J. 2004;23(5):723–9.CrossRefPubMed
45.
Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12(6):1322–6.CrossRefPubMed
46.
Rutten-van Mölken M, Postma M, Joore M, Van Genugten M, Leidl R, Jager J. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med. 1999;93(11):779–87.CrossRefPubMed
47.
48.
Petrou P, Vandoros S. Cyprus in crisis: recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment. Health Policy. 2015;119(5):563–8.CrossRefPubMed
Metadata
Title
The economic burden of adult asthma in Cyprus; a prevalence-based cost of illness study
Authors
Savvas Zannetos
Theodora Zachariadou
Andreas Zachariades
Andreas Georgiou
Michael A. Talias
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2017
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-017-4184-0

Other articles of this Issue 1/2017

BMC Public Health 1/2017 Go to the issue

Research article

‘Foreigners’, ‘ethnic minorities’, and ‘non-Western allochtoons’: an analysis of the development of ‘ethnicity’ in health policy in the Netherlands from 1970 to 2015

Research article

Development of a theory and evidence-based program to promote community treatment of fevers in children under five in a rural district in Southern Ghana: An intervention mapping approach

Research article

Behavioral antecedents for handwashing in a low-income urban setting in Bangladesh: an exploratory study

Research article

Effect of prohibiting the use of Paraquat on pesticide-associated mortality

Research article

Systematic development and implementation of interventions to OPtimise Health Literacy and Access (Ophelia)

Research article

Using a monitoring and evaluation framework to improve study efficiency and quality during a prospective cohort study in infants receiving rotavirus vaccination in El Alto, Bolivia: the Infant Nutrition, Inflammation, and Diarrheal Illness (NIDI) study